Linkage Projects - Grant ID: LP0668335

Funding Activity

Website
http://dataportal.arc.gov.au/NCGP/Web/Grant/Grant/LP0668335

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Molecular response to interferon beta treatment in multiple sclerosis. Inteferon beta (IFNb) is the frontline drug for treatment of multiple sclerosis. However, in many patients this expensive drug provides no benefit, resulting in unnecessary, uncontrolled disease progression, and in a waste of many millions of dollars each year. A common explanation for this treatment failure is the development of neutralising antibodies (NABs). We will establish the prevalence and effects of NABs in Australian patients, use novel techniques to identify biomarkers for IFNb response, evaluate the diagnostic and therapeutic value of the biomarkers, and develop a new test for NABs. Tailored use of this drug, and possible new therapeutic targets, will result, benefiting the patient and community.

Funded Activity Details

Start Date: 18-08-2006

End Date: 04-08-2011

Funding Scheme: Linkage Projects

Funding Amount: $411,000.00

Funder: Australian Research Council

Research Topics

ANZSRC Field of Research (FoR)

Central Nervous System | Clinical Pharmacology And Therapeutics | Medical Genetics | Neurosciences

ANZSRC Socio-Economic Objective (SEO)

Immune system and allergy | Diagnostics | Treatments (e.g. chemicals, antibiotics) |

Other Keywords

Central Nervous System | Clinical Pharmacology And Therapeutics | Diagnostics | Immune system and allergy | Medical Genetics | Neurosciences | Treatments (e.g. chemicals, antibiotics)

Related Links